ReviveRX Pharmacy
Revive Rx LLC d/b/a Revive Rx Pharmacy · Houston, TX · operating since 2016
We do not sell medication and we have no commercial relationship with ReviveRX Pharmacy. Everything below is either published by a regulator or published by the pharmacy about itself, labelled as such and dated. We give you the official lookups rather than asking you to take our word for the current position.
The short answer
- ReviveRX Pharmacy is the trading name of Revive Rx LLC d/b/a Revive Rx Pharmacy, based in Houston, TX. Regulators file under the legal name, so search that.
- Registration: 503A. ReviveRX describes itself as a licensed 503A mail-order compounding pharmacy preparing individualised medications against a prescriber’s prescription, in USP-compliant clean rooms at its Houston headquarters. It is not a registered 503B outsourcing facility.
- FDA warning letter: 709509 (September 22, 2025). Read the dates and which site each one covers — both are material.
- Compounded semaglutide and tirzepatide are NOT FDA-approved as finished products, whichever pharmacy prepares them. FDA does not review them for safety, effectiveness or manufacturing quality.
Registration and licence
ReviveRX describes itself as a licensed 503A mail-order compounding pharmacy preparing individualised medications against a prescriber’s prescription, in USP-compliant clean rooms at its Houston headquarters. It is not a registered 503B outsourcing facility.
Regulatory record
Every item below is a public document, linked to its source, with the date it was issued and the dates of any inspection behind it. Where the agency recorded the company's response, a completed recall, or which legal entity a record actually concerns, that is included — leaving it out would misrepresent the record. Where the company has answered publicly, its answer is printed too.
- FDA warning letter709509
FDA issued a warning letter to Revive Rx LLC dba Revive Rx Pharmacy. It follows the January-February 2025 inspection of the Houston facility recorded below.
Which entity this concerns: Note the sequence: the Form 483 observations came first, in February 2025, and the warning letter followed in September 2025. That is the escalation path a 483 can take when FDA is not satisfied with the response.
Our check on July 29, 2026 did not surface a published close-out. That means we did not find one, not that none exists.
Read it on fda.gov - FDA Form 483 (observations)Form 483, Revive Rx LLC dba Revive Rx Pharmacy, Houston TX
From an inspection running 2025-01-27 to 2025-02-07.
Investigator observations included environmental-monitoring practice during production of a named semaglutide lot (Semaglutide 5 mg/mL 2 cc, lot 10453555), media fills that the report found were not representative of the batch size, container type and equipment actually used — with no media fill at all for syringe products — cleaning of the biological safety cabinet between two named products that the report considered inadequate to prevent cross-contamination, and lyophilizers not sterilised by routine sterilisation cycles.
Which entity this concerns: This is the only record in this set where FDA observations name a semaglutide lot directly, rather than concerning other compounded products at the same site.
Context FDA published with it: A Form 483 records an investigator’s observations and does not represent a final agency determination regarding compliance.
The company's response: ReviveRX’s website lists "successful FDA inspection" among its compliance credentials. We report that as the company’s own description; readers can weigh it against the published record above and reach their own view.
Our check on July 29, 2026 did not surface a published close-out. That means we did not find one, not that none exists.
Read it on fda.gov
What it compounds for GLP-1 patients
- · Compounded semaglutide
- · Compounded sermorelin and other peptides
Compounded semaglutide and tirzepatide are not FDA-approved as finished drug products. FDA does not review them for safety, effectiveness or manufacturing quality before they reach patients. That applies to every compounded GLP-1 regardless of which pharmacy prepares it, and it is a separate question from whether the pharmacy is licensed.
If you would rather not take that trade, the FDA-approved oral products now start at $149/month direct from their manufacturers — see the cheapest routes compared.
Check it yourself
Search under the legal name — Revive Rx LLC d/b/a Revive Rx Pharmacy — not the brand. Regulators file under the legal entity, and searching the trading name alone is how records get missed.
- FDA — Registered Outsourcing Facilities (503B)
The authoritative list of pharmacies registered with the FDA as 503B outsourcing facilities (the higher-oversight compounding tier). If a pharmacy claims to be 503B, it should appear here.
- FDA — 503A vs 503B explainer
What the two compounding categories mean: 503A = patient-specific prescriptions under state board oversight; 503B = larger-batch outsourcing facilities under direct FDA cGMP inspection.
- FDA — Warning Letters search
Search the FDA’s public warning-letter database by company name to see whether a pharmacy has an open compliance action. Confirm the date and status — letters can be resolved.
- NABP — Verify a pharmacy / .pharmacy
The National Association of Boards of Pharmacy tools flag rogue online pharmacies and list accredited ones. Legitimate US pharmacies are licensed by a state board.
- LegitScript — Certification lookup
LegitScript certifies healthcare merchants that meet legal + safety standards. Many reputable telehealth GLP-1 providers display a LegitScript badge you can verify here.
- Your state Board of Pharmacy
Every US pharmacy must be licensed by the state board where it operates (and often where it ships). State boards publish license status + disciplinary history.
Questions people ask about ReviveRX Pharmacy
Is ReviveRX Pharmacy a licensed pharmacy?
We have not been able to verify a published state licence record for ReviveRX Pharmacy. Use your state board of pharmacy's lookup to check before buying.
What is the regulatory record for ReviveRX Pharmacy?
FDA issued warning letter 709509 on September 22, 2025. FDA issued a warning letter to Revive Rx LLC dba Revive Rx Pharmacy. It follows the January-February 2025 inspection of the Houston facility recorded below. Our check on July 29, 2026 did not surface a published close-out letter, which means we did not find one — not that none exists.
Is a Form 483 the same as a warning letter?
No, and the difference matters. A Form 483 is the list of observations an FDA investigator leaves at the end of an inspection. It records what the investigator saw, not an agency finding that the law was broken. A warning letter comes later and states FDA's position that violations occurred. Firms respond to 483s and many are resolved without a warning letter ever being issued.
Does ReviveRX Pharmacy make FDA-approved GLP-1 medication?
No compounding pharmacy does. ReviveRX Pharmacy publicly compounds compounded semaglutide and compounded sermorelin and other peptides. Compounded drugs are not FDA-approved: the agency does not review them for safety, effectiveness or manufacturing quality before they reach patients. That is true of every compounded product regardless of which pharmacy prepares it, and it is a different thing from the pharmacy being licensed or unlicensed.
How do I check ReviveRX Pharmacy myself?
Three free lookups settle it: the FDA warning-letter database, searched by the legal name (Revive Rx LLC d/b/a Revive Rx Pharmacy) rather than the trading name; the FDA list of registered 503B outsourcing facilities, if the pharmacy claims 503B status; and your state board of pharmacy's licence verification. All three are linked at the bottom of this page. Check the legal name — regulators file under it, and searching the brand alone misses records.